Skip to main content
Pellmoor

Medical Weight Management

Obesity is a chronic disease. We treat it like one.

Appetite is regulated by hormones, not willpower. GLP-1 and dual-agonist medications work on that biology — and they work best inside a program that also protects your muscle, tracks your labs, and adjusts your dose based on how you actually feel.

$149/month for careVideo or asyncMedication separate

What your membership actually includes

  • Initial 30-minute video visit with a licensed physician or nurse practitioner
  • Personalized treatment plan and prescription when clinically appropriate
  • Unlimited secure messaging with your care team
  • Monthly follow-up visits
  • Dose titration and side-effect management
  • Nutrition and resistance-training guidance to protect lean mass
  • Prescriptions sent to the pharmacy of your choice

What it does not include

  • The cost of medication — you pay your pharmacy directly
  • Laboratory fees — billed by the lab at transparent cash rates
  • Any service requiring an in-person examination

On medication cost — the honest version

Brand GLP-1 medication is expensive. Without insurance coverage, monthly cash prices commonly run several hundred dollars or more, depending on the product, the dose, the pharmacy, and any manufacturer savings program you qualify for.

We will tell you the realistic range for your specific situation before you pay us anything. If the cost does not work for you, we will say so rather than sell you a membership you cannot use.

We do not prescribe compounded GLP-1s

Compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed for safety, effectiveness, or quality. The FDA shortage declarations that permitted broad compounding of these molecules have ended. We prescribe manufacturer-produced product only.

Protecting muscle is part of treatment

A substantial share of weight lost on these medications is lean mass. Your plan includes a protein target and a resistance-training prescription. We consider this a clinical requirement, not a wellness upsell.

Injection or pill

A weekly injection, or a daily tablet

If needles are a dealbreaker, you have options. Two GLP-1 medications are FDA-approved for weight management as a once-daily pill. Tell us your preference at your visit — your clinician will go through which fits your health, your other medicines, and your budget.

Weekly injection

Wegovy®, Zepbound®

How often
Once a week, same day each week
How you take it
A small prefilled pen, under the skin of the belly, thigh or upper arm
Food and timing
Any time of day, with or without food
Dose steps
Increases every 4 weeks toward a maintenance dose

The longest track record of the three.

Wegovy® pill

semaglutide tablet — the same medicine as the Wegovy® injection

How often
Once a day, every morning
How you take it
Swallow one tablet whole
Food and timing
On an empty stomach with up to 4 oz of plain water, then nothing else — food, drink or other medicines — for 30 minutes
Dose steps
1.5 → 4 → 9 → 25 mg, 30 days per step

The morning routine is what makes it work. If that is hard to keep, the injection or Foundayo™ may suit you better.

Foundayo™

orforglipron tablet, approved April 2026

How often
Once a day
How you take it
Swallow one tablet whole
Food and timing
Any time of day, with or without food
Dose steps
0.8 → 2.5 → 5.5 mg, then higher only if needed, at least 30 days per step

If you use birth control pills, you will need a backup method for 30 days after starting and after each dose increase.

Same safety rules, pill or pen

The tablets carry the same boxed warning, contraindications and monitoring as the injections, and you can only be on one GLP-1 at a time. Switching between them is possible, and your clinician will plan the changeover.

Cost differs by product

Cash prices vary by medication, dose and pharmacy, and each manufacturer runs its own self-pay program. We will go through the options with you before you commit. See also ways to pay less for your medication.

Your first 12 weeks

What happens, and when

  1. Week 0

    Eligibility check, baseline labs (A1c, CMP, lipids, TSH, pregnancy test where applicable), 30-minute video visit, and your Good Faith Estimate.
  2. Weeks 1–4

    Starting dose. Weekly portal check-in on weight and side effects. Message us any time — nausea is manageable and we would rather adjust than have you quit.
  3. Weeks 4–8

    First dose escalation only if you tolerated the current step. Protein and resistance-training plan reviewed.
  4. Week 12

    Repeat A1c and CMP. Full clinician review. If you have lost less than 5% of your starting weight on a maintenance dose, we change the plan rather than continue on autopilot.

Published clinical protocol

Medical Weight Management

Physician-supervised obesity care combining nutrition, activity, behavioral support, and — when indicated — incretin-based pharmacotherapy. Anti-obesity medication is an adjunct to lifestyle therapy, never a substitute for it.

Who is eligible

  • Age 18 or older.
  • BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, metabolic dysfunction-associated steatotic liver disease, osteoarthritis, or established cardiovascular disease).
  • Physically located in Illinois or Indiana at the time of each visit.
  • Able to participate in a synchronous audio-video encounter.
  • Verified government-issued photo identification on file.

Labs we require

  • Hemoglobin A1c · baseline
  • Comprehensive metabolic panel (renal + hepatic) · baseline
  • Fasting lipid panel · baseline
  • TSH · baselineScreens for thyroid contributors to weight change.
  • Pregnancy test · baselineRequired for patients of childbearing potential before initiation and as clinically indicated.
  • Lipase · as indicatedIf abdominal pain develops.
  • A1c + CMP · 3 months
  • Full metabolic reassessment · annual

Absolute contraindications

If any of these apply, we will not prescribe. No exceptions.

  • Personal or family history of medullary thyroid carcinoma

    Boxed warning: GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. Human relevance undetermined.

  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

    Shares the boxed warning above.

  • Prior serious hypersensitivity reaction to the agent

    Anaphylaxis and angioedema reported.

  • Pregnancy, attempting conception, or breastfeeding

    Weight loss offers no benefit in pregnancy and may cause fetal harm. Discontinue at least 2 months before a planned pregnancy for semaglutide.

Requires extra evaluation

  • History of pancreatitis — Acute pancreatitis reported post-marketing. Requires documented risk/benefit discussion and heightened symptom counseling.
  • Gastroparesis or severe gastrointestinal motility disorder — Incretins delay gastric emptying and may worsen symptoms.
  • Diabetic retinopathy — Rapid glycemic improvement has been associated with transient worsening. Requires ophthalmology co-management.
  • Active or historical eating disorder — Requires behavioral health assessment before initiation; screened at intake with the SCOFF instrument.
  • Symptomatic cholelithiasis — Rapid weight loss increases gallstone risk. Counsel on symptoms.
  • Significant renal impairment (eGFR < 30) — Volume depletion from GI losses can precipitate acute kidney injury.
  • Concurrent insulin or sulfonylurea — Hypoglycemia risk; requires dose reduction and glucose monitoring coordination with the prescribing clinician.

Medications on protocol

semaglutide (once-weekly injection)

Brands: Wegovy, Ozempic — trademarks of Novo Nordisk A/S

Route: Subcutaneous, once weekly

FDA-approved for

  • Wegovy: chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity; cardiovascular risk reduction in adults with established CVD and overweight/obesity.
  • Ozempic: glycemic control in type 2 diabetes mellitus, and associated cardiovascular risk reduction.

Off-label: Ozempic prescribed for weight management is an OFF-LABEL use and is disclosed to the patient as such in the consent.

Boxed warning

Risk of thyroid C-cell tumors. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.

Titration

  1. 0.25 mg weekly × 4 weeks
  2. 0.5 mg weekly × 4 weeks
  3. 1.0 mg weekly × 4 weeks
  4. 1.7 mg weekly × 4 weeks
  5. 2.4 mg weekly maintenance
  6. Hold escalation for intolerable GI effects; extend any step as needed.

semaglutide (once-daily tablet)

Brands: Wegovy — trademarks of Novo Nordisk A/S

Route: Oral, once daily — on an empty stomach in the morning with up to 4 oz of water; nothing else by mouth for 30 minutes

FDA-approved for

  • Wegovy tablets: chronic weight management in adults with BMI ≥30, or ≥27 with a weight-related comorbidity; cardiovascular risk reduction in adults with established CVD and overweight/obesity.

Boxed warning

Risk of thyroid C-cell tumors. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.

Titration

  1. 1.5 mg daily, days 1–30
  2. 4 mg daily, days 31–60
  3. 9 mg daily, days 61–90
  4. 25 mg daily maintenance from day 91
  5. If 25 mg is not tolerated, consider switching to Wegovy injection 1.7 mg weekly rather than continuing a lower tablet dose.

orforglipron (once-daily tablet)

Brands: Foundayo — trademarks of Eli Lilly and Company

Route: Oral, once daily, any time of day, with or without food

FDA-approved for

  • Foundayo: chronic weight management in adults with obesity, or overweight with at least one weight-related comorbid condition.

Boxed warning

Risk of thyroid C-cell tumors. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.

Titration

  1. 0.8 mg daily for at least 30 days
  2. 2.5 mg daily for at least 30 days
  3. 5.5 mg daily — may be continued as maintenance
  4. 9 mg → 14.5 mg → 17.2 mg daily, escalating no sooner than every 30 days, by response and tolerability
  5. Maximum 17.2 mg daily; maximum 9 mg daily with a strong CYP3A4 inhibitor.

tirzepatide (once-weekly injection)

Brands: Zepbound, Mounjaro — trademarks of Eli Lilly and Company

Route: Subcutaneous, once weekly

FDA-approved for

  • Zepbound: chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity.
  • Mounjaro: glycemic control in type 2 diabetes mellitus.

Boxed warning

Risk of thyroid C-cell tumors. Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.

Titration

  1. 2.5 mg weekly × 4 weeks
  2. 5 mg weekly × 4 weeks
  3. 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly, escalating no faster than every 4 weeks as tolerated

metformin, bupropion/naltrexone, phentermine (state-dependent)

Brands: Glucophage, Contrave, Adipex-P — trademarks of Respective manufacturers

Route: Oral

FDA-approved for

  • Agent-specific. Phentermine is a Schedule IV controlled substance and is NOT prescribed via telehealth on this platform.

Titration

  1. Per individual package insert and Medical Director standing protocol.

How we monitor you

  • — Weekly patient-reported weight and side-effect check-in through the portal for the first 12 weeks.
  • — Clinician review at weeks 4, 8, and 12, then at least every 3 months.
  • — Escalate dose only after documented tolerance at the current dose.
  • — Reassess at 12 weeks on the maintenance dose: if weight loss is < 5% of baseline, reassess the regimen rather than continuing indefinitely.
  • — Counsel on protein intake (≥ 1.0–1.5 g/kg ideal body weight) and resistance training to preserve lean mass.
  • — Screen for depression and suicidality at baseline (PHQ-9) and at each quarterly review.

When to stop and get help immediately

  • Severe persistent abdominal pain radiating to the back → stop medication, obtain lipase, refer for urgent evaluation.
  • Signs of anaphylaxis or angioedema → stop immediately, 911.
  • Suspected bowel obstruction (persistent vomiting, no flatus) → emergency department.
  • Any pregnancy → stop immediately, contact clinician same day.
  • Suicidal ideation on PHQ-9 item 9 → same-day behavioral health protocol, 988 resources provided.

Protocol weight-management · version 1.1 · last reviewed 2026-09-14 · approved by the Medical Director. Clinicians may deviate from protocol with documented clinical rationale.

Questions people actually ask

Will I qualify?

You need a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes or diabetes, high cholesterol, or sleep apnea. The free eligibility check calculates this and tells you immediately.

Is Ozempic® the same as Wegovy®?

Same molecule — semaglutide — but different FDA-approved indications and dosing. Wegovy® is approved for weight management; Ozempic® is approved for type 2 diabetes. Prescribing Ozempic® for weight loss is off-label. Legal, common, and disclosed to you in writing before you consent.

Is there a pill instead of an injection?

Yes. The Wegovy® pill and Foundayo™ are both FDA-approved for weight management and taken once a day by mouth. See how they compare with the weekly injection. Your clinician decides with you which is appropriate.

What happens if I stop?

Most people regain a substantial portion of the weight. That is physiology, not failure. These medications treat a chronic condition and are intended for long-term use. We will tell you this before you start, not after.

Can I use my HSA or FSA?

Generally yes — medical care from a licensed clinician is typically a qualified expense. We provide itemized receipts. Confirm with your plan administrator.

Do you take my insurance?

No. We bill no insurance of any kind, including Medicare and Medicaid. You may submit our itemized receipt to your insurer yourself for possible out-of-network reimbursement, but we make no promises about whether they will pay.

What if the medication is out of stock?

We will work with you on alternative pharmacies and, if clinically appropriate, an alternative agent. We will not substitute a compounded version.